178 related articles for article (PubMed ID: 37900570)
41. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
Kondo T; Wang X; Yang M; Jhund PS; Claggett BL; Vaduganathan M; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Langkilde AM; Petersson M; Zaozerska N; Bachus E; Solomon SD; McMurray JJV
J Am Coll Cardiol; 2023 Sep; 82(10):1014-1026. PubMed ID: 37610398
[TBL] [Abstract][Full Text] [Related]
42. Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice.
Erdem S; Titus A; Patel D; Patel NN; Sattar Y; Glazier J; Alraies MC
Cureus; 2023 Apr; 15(4):e37310. PubMed ID: 37182087
[TBL] [Abstract][Full Text] [Related]
43. Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies.
Deng Y; Zhang J; Ling J; Hu Q; Song T; Xu Y; Liu M; Wu Y; Mei K; Chen J; Zhao H; Liu X
Front Cardiovasc Med; 2023; 10():1257335. PubMed ID: 38250027
[TBL] [Abstract][Full Text] [Related]
44. Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials.
Camilli M; Lombardi M; Chiabrando JG; Zito A; Del Buono MG; Vergallo R; Aspromonte N; Lombardo A; Montone RA; Niccoli G; Biondi-Zoccai G; Crea F; Minotti G
Am J Ther; 2021 Nov; 29(2):e199-e204. PubMed ID: 35389572
[TBL] [Abstract][Full Text] [Related]
45. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
Yan Y; Liu B; Du J; Wang J; Jing X; Liu Y; Deng S; Du J; She Q
ESC Heart Fail; 2021 Jun; 8(3):2210-2219. PubMed ID: 33749159
[TBL] [Abstract][Full Text] [Related]
46. Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment.
Oh J; Lee SH; Lee CJ; Kang SM
Korean Circ J; 2021 May; 51(5):399-408. PubMed ID: 33975387
[TBL] [Abstract][Full Text] [Related]
47. SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhao Z; Jin P; Zhang Y; Hu X; Tian C; Liu D
Front Cardiovasc Med; 2022; 9():826684. PubMed ID: 35557542
[TBL] [Abstract][Full Text] [Related]
48. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
[TBL] [Abstract][Full Text] [Related]
49. Prevalence and Prognostic Implication of Atrial Fibrillation in Heart Failure Subtypes: Systematic Review and Meta-Analysis.
Mundisugih J; Franke KB; Tully PJ; Munawar DA; Kumar S; Mahajan R
Heart Lung Circ; 2023 Jun; 32(6):666-677. PubMed ID: 37003940
[TBL] [Abstract][Full Text] [Related]
50. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
51. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
[TBL] [Abstract][Full Text] [Related]
52. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis.
Lauritsen J; Gustafsson F; Abdulla J
ESC Heart Fail; 2018 Aug; 5(4):685-694. PubMed ID: 29660263
[TBL] [Abstract][Full Text] [Related]
53. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
Yang M; Butt JH; Kondo T; Jering KS; Docherty KF; Jhund PS; de Boer RA; Claggett BL; Desai AS; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Langkilde AM; Martinez FA; Petersson M; Shah SJ; Vaduganathan M; Wilderäng U; Solomon SD; McMurray JJV
Eur J Heart Fail; 2022 Dec; 24(12):2307-2319. PubMed ID: 36342375
[TBL] [Abstract][Full Text] [Related]
54. Clinical characteristics and outcomes in Asian patients with heart failure with mildly reduced ejection fraction.
Tay JCK; Chia SY; Koh SHM; Sim DKL; Chai P; Loh SY; Jaufeerally FR; Lee SSG; Lim PZY; Yap J
Singapore Med J; 2024 Jul; 65(7):389-396. PubMed ID: 37338492
[TBL] [Abstract][Full Text] [Related]
55. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
56. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
57. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM
Drugs Context; 2023; 12():. PubMed ID: 36660013
[TBL] [Abstract][Full Text] [Related]
58. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
59. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Zhang N; Wang Y; Chen Z; Letsas KP; Tse G; Li G; Lip GYH; Liu T; Korantzopoulos P
Europace; 2022 Jan; 24(1):20-30. PubMed ID: 34333592
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis.
Mo X; Lu P; Yang X
Clin Cardiol; 2023 Oct; 46(10):1137-1145. PubMed ID: 37465885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
